Literature DB >> 17003644

The ratio of metastatic/resected lymph nodes is an independent prognostic factor in patients with node-positive pancreatic head cancer.

Marek Sierzega1, Tadeusz Popiela, Jan Kulig, Krystyna Nowak.   

Abstract

OBJECTIVES: The aim of this study was to evaluate the prognostic value of nodal involvement in resected adenocarcinoma of the pancreatic head.
METHODS: For the period between 1980 and 2002, 96 patients underwent pancreaticoduodenectomy for pancreatic cancer. Lymph nodes were numbered and classified into groups according to the Japan Pancreatic Society rules. Metastatic lymph nodes were identified based on hematoxylin and eosin staining.
RESULTS: Sixty-four (66.7%) patients had positive lymph nodes. The median number of metastatic nodes was 2 (95% confidence interval [CI], 1.0-3.0) and the median ratio of metastatic/resected nodes was 9.7% (95% CI, 7.1%-14.4%). The median survival was 14.2 months (95% CI, 10.7-17.7) and was significantly higher for node-negative than node-positive patients (27.9; 95% CI, 20.9-34.9 vs. 10.6; 95% CI, 8.7-12.5; P < 0.001). The Cox proportional hazards model, including all patients, demonstrated that nodal involvement (hazard ratio [HR], 1.461; 95% CI, 1.177-12.024), moderate or poor tumor differentiation (HR, 2.330; 95% CI, 1.181-6.949), and positive resection margins (HR, 3.838; 95% CI, 1.390-10.597) were independent negative prognostic factors. If the analysis was limited to node-positive patients, lymph node ratio of more than 20% (HR, 1.364; 95% CI, 1.116-2.599), moderate or poor tumor differentiation (HR, 3.393; 95% CI, 1.041-11.061), and positive resection margins (HR, 9.400; 95% CI, 2.235-39.536) significantly correlated with a poorer survival.
CONCLUSIONS: Lymph node ratio seems to be a new promising prognostic factor in patients with respectable node-positive pancreatic head cancer.

Entities:  

Mesh:

Year:  2006        PMID: 17003644     DOI: 10.1097/01.mpa.0000235306.96486.2a

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  41 in total

1.  Extended pancreatic resections and lymphadenectomy: An appraisal of the current evidence.

Authors:  Shailesh V Shrikhande; Savio G Barreto
Journal:  World J Gastrointest Surg       Date:  2010-02-27

Review 2.  The lymphatic system and pancreatic cancer.

Authors:  Darci M Fink; Maria M Steele; Michael A Hollingsworth
Journal:  Cancer Lett       Date:  2015-12-29       Impact factor: 8.679

3.  Use of multifunctional sigma-2 receptor ligand conjugates to trigger cancer-selective cell death signaling.

Authors:  Dirk Spitzer; Peter O Simon; Hiroyuki Kashiwagi; Jinbin Xu; Chenbo Zeng; Suwanna Vangveravong; Dong Zhou; Katherine Chang; Jonathan E McDunn; John R Hornick; Peter Goedegebuure; Richard S Hotchkiss; Robert H Mach; William G Hawkins
Journal:  Cancer Res       Date:  2011-11-07       Impact factor: 12.701

4.  Re-evaluating the impact of tumor size on survival following pancreaticoduodenectomy for pancreatic adenocarcinoma.

Authors:  Mechteld C de Jong; Fuyu Li; John L Cameron; Christopher L Wolfgang; Barish H Edil; Joseph M Herman; Michael A Choti; Frederick Eckhauser; Kenzo Hirose; Richard D Schulick; Timothy M Pawlik
Journal:  J Surg Oncol       Date:  2011-01-31       Impact factor: 3.454

5.  Determining pattern of recurrence following pancreaticoduodenectomy and adjuvant 5-flurouracil-based chemoradiation therapy: effect of number of metastatic lymph nodes and lymph node ratio.

Authors:  Bolanle Asiyanbola; Ana Gleisner; Joseph M Herman; Michael A Choti; Christopher L Wolfgang; Michael Swartz; Barish H Edil; Richard D Schulick; John L Cameron; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2008-12-17       Impact factor: 3.452

6.  Prognostic value of the lymph node ratio after resection of periampullary carcinomas.

Authors:  Shahid G Farid; Gavin A Falk; Daniel Joyce; Sricharan Chalikonda; R Matthew Walsh; Andrew M Smith; Gareth Morris-Stiff
Journal:  HPB (Oxford)       Date:  2012-11-19       Impact factor: 3.647

7.  Clinical and pathologic features influencing survival in patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma.

Authors:  Cynthia E Weber; Eileen A Bock; Michael G Hurtuk; Gerard J Abood; Jack Pickleman; Margo Shoup; Gerard V Aranha
Journal:  J Gastrointest Surg       Date:  2013-11-23       Impact factor: 3.452

8.  Factors predicting long-term survival following pancreatic resection for ductal adenocarcinoma of the pancreas: 40 years of experience.

Authors:  Niloufar Dusch; Christel Weiss; Philip Ströbel; Peter Kienle; Stefan Post; Marco Niedergethmann
Journal:  J Gastrointest Surg       Date:  2013-11-16       Impact factor: 3.452

9.  N0/N1, PNL, or LNR? The effect of lymph node number on accurate survival prediction in pancreatic ductal adenocarcinoma.

Authors:  Nakul P Valsangkar; Devon M Bush; James S Michaelson; Cristina R Ferrone; Jennifer A Wargo; Keith D Lillemoe; Carlos Fernández-del Castillo; Andrew L Warshaw; Sarah P Thayer
Journal:  J Gastrointest Surg       Date:  2012-12-11       Impact factor: 3.452

10.  Lymph node ratio versus number of affected lymph nodes as predictors of survival for resected pancreatic adenocarcinoma.

Authors:  Imran Bhatti; Oliver Peacock; Altaf K Awan; David Semeraro; Michael Larvin; Richard I Hall
Journal:  World J Surg       Date:  2010-04       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.